Physician profile
Chloe S Datillo
NPI 1366096703
$9,960.74
in general payments reported to CMS, 2019-2025
43 companies · $1,801 in 2025
The $1,801 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,657 · 2022: $1,498 · 2023: $1,800 · 2024: $2,205 · 2025: $1,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,806.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,394.85 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $807.38 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $652.26 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $610.93 | 2021-2025 | Jardiance |
| Abbvie INC. | $600.43 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $595.35 | 2022-2025 | Lifevest |
| Esperion Therapeutics, INC. | $533.08 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $495.98 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $390.03 | 2022-2025 | Farxiga, Brilinta, Wainua |
| Amarin Pharma, INC. | $324.12 | 2021-2022 | |
| Amgen INC. | $322.04 | 2021-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $315.67 | 2021-2025 | |
| Lilly USA, LLC | $272.06 | 2021 | |
| Novo Nordisk INC | $258.61 | 2021-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $250.93 | 2022-2024 | Xarelto |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $233.53 | 2021-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $223.30 | 2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $217.57 | 2021-2025 | Corevalve Evolut R, Linq II |
| Scpharmaceuticals INC. | $180.57 | 2023-2025 | |
| Biogen, INC. | $156.93 | 2021 | |
| Glaxosmithkline, LLC. | $135.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.71 | 2021 | |
| Kestra Medical Technology Services, INC. | $97.47 | 2023-2025 | Assure Wcd |
| Dexcom, INC. | $85.49 | 2021 | |
| Sunovion Pharmaceuticals INC. | $73.67 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $72.78 | 2021 | |
| Boston Scientific Corporation | $65.30 | 2024 | Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.70 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $52.03 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $51.63 | 2023-2024 | Inpefa |
| Endo Pharmaceuticals INC. | $49.21 | 2021-2022 | |
| Vifor Pharma, INC. | $45.36 | 2022 | |
| Eisai INC. | $44.34 | 2021-2022 | |
| Atricure, INC. | $31.24 | 2025 | Atricure Cryoice Cryoablation System (Cryo2), Atricure Cryoice Cryosphere Cryoablation System, Atriclip Laa Exclusion System |
| Alnylam Pharmaceuticals INC. | $21.31 | 2025 | Amvuttra |
| Alexion Pharmaceuticals, INC. | $19.18 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $19.02 | 2023 | Opsumit |
| Cvrx, INC. | $15.67 | 2024 | Barostim Neo System |
| Heartflow, INC. | $15.64 | 2024 | |
| Astellas Pharma US INC | $15.44 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.02 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.27 | 2021 | |
| Mylan Specialty L.P. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Datillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.